ClinicalTrials.gg
CompletedNCT04621669Updated Jun 5, 2026

Drug-durg Interaction of SHR3680 With Digoxin, Rosuvastatin Calcium and Metformin Hydrochloride

A Phase 1 interventional study of SHR3680 and digoxin in Drug-drug Interaction,SHR3680, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Male
01

Study summary

The DDI study had been designed to investigate the effect of SHR3680 on the pharmacokinetics of digoxin, Rosuvastatin calcium and metformin hydrochloride.

02

Conditions studied

  • Drug-drug Interaction,SHR3680
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet all of the following criteria to enter the study:

  1. 18 ≤ age ≤75, male;
  2. score of physical condition is 0 \~ 1;
  3. The expected survival time is at least 3 months;
  4. Prostate adenocarcinoma confirmed by histological or cytological examination (can be included in mHSPC and mCRPC populations), with no neuroendocrine or small-cell characteristics;CRPC should also meet the following two conditions :(1) serum testosterone level of castration (\< 1.7 nmol/L);(2) biochemical progression: prostate-specific antigen (PSA) was increased for 3 consecutive times at an interval of 1 week or more, and increased by more than 50% compared with the lowest value for 2 consecutive times, with PSA > 2 g/L.Or imaging progress: 2 or more new lesions or soft tissue lesions conforming to solid tumor response evaluation criteria were found on bone scan;
  5. The functional level of organs must meet the following requirements (no blood transfusion or hematopoietic growth factor treatment was received within 2 weeks before routine blood screening) :

    • the ANC ≧ 1.5 x 109 / L;
    • ≧ 80 x 109 / L;
    • ≧ 90 g/L; 1.5 x - ≦;
    • and AST≦2.5×ULN;
    • 1.5 x ULN Cr ≦;
    • ≧ 60 ml/min / 1.73 m2.
  6. According to the researcher's judgment, it can comply with the experimental scheme;
  7. In addition, in accordance with the requirements of regulatory authorities, research centers and relevant departments, and based on the judgment of researchers, you shall be tested for COVID-19 screening when necessary;
  8. Volunteer to participate in this clinical trial, understand the study procedures and have signed .

Exclusion criteria

Exclusion Criteria:

Subjects who meet any of the following criteria will not be admitted to the study:

  1. Any previous anti-tumor therapy (including radiotherapy, chemotherapy, surgery, molecular targeted therapy, immunotherapy, etc.), except ADT therapy, shall be completed until the of the first drug administration in this study is \<4 weeks;
  2. Plan to receive any other anti-tumor therapy during the study;
  3. As subjects, to participate in other drug clinical trials, the last trial drug administration is less than 4 weeks from the first administration of the drug in this study (except for the patients who have participated in ADT treatment before and have been out of the group, and the subjects who are still giving free ADT treatment);
  4. The presence of intracerebral tumor lesions according to imaging diagnosis;
  5. Have a history of epilepsy, or have diseases that can induce epileptic seizures within 12 months before the first administration of the drug in this study (including a history of , cerebral stroke (except cerebral ischemia lesions found by simple imaging examination), and need to be hospitalized with cerebral trauma and consciousness disorder);
  6. Active heart disease, including severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, and drug-requiring ventricular arrhythmias, within 6 months prior to the first administration of the drug in this study;
  7. Inability to swallow, chronic diarrhea and ileus, history of gastrointestinal surgery, or other factors affecting drug use and absorption as determined by the investigator;
  8. Patients with active or infection (HBsAg positive and virus copy number ≥500 IU/mL, HCV antibody positive and HCV RNA higher than the lower limit of analytical method detection) and active syphilis;
  9. A history of immunodeficiency (including positive, other acquired or congenital immunodeficiency diseases) or a history of organ transplantation;
  10. Patients who were unwilling to use effective methods during the whole study treatment period and within 3 months after the last administration;
  11. Allergic constitution, including a history of severe drug allergy or drug allergy;
  12. Screening for excessive smoking in the first 6 months (≥5 cigarettes/day) or smoking within 48 hours before the first dose, or not interrupting smokers during the main study trial, and screening for drug use in the first 3 months with a history of drug abuse or positive drug abuse screening;
  13. has a history of alcoholism or within 6 months prior to screening often drinkers, namely the essence of drinking more than 14 units of alcohol a week (1 = 285 mL of alcohol content of 5% beer or 25 mL of 40% alcohol liquor or 100 mL wine alcohol content of 12%) or within 48 h before taking the medicine for the first time drinking, or D - 1 in the alcohol breath test positive, or the body can't stop alcohol intake during the study period;
  14. Use of any vitamin product, health product or herb 14 days prior to the first administration;
  15. Ingestion of grapefruit or fruit juice products such as grapefruit, foods or beverages containing caffeine, xanthine or alcohol within 48 hours before taking the study drug;Strenuous exercise, or other factors affecting drug absorption, distribution, metabolism, and excretion;
  16. Within 2 weeks before the first drug uptake, uptake transporter P-GP, BCRP, OATP1B1/1B3 or MATE1/2-K inhibitors were used, or drugs affecting gastric acid secretion.(Annex I);
  17. abnormal coagulation function at screening stage ( >1.5 or prothrombin time (PT) > +4 seconds or APTT> 1.5uln), bleeding tendency or thrombolytic therapy;
  18. Patients with a history of fainting needle or blood, have difficulty in blood collection or cannot tolerate vein puncture for blood collection;
  19. Concomitant diseases (such as poorly controlled hypertension, severe diabetes, thyroid disease, psychosis, etc.) or any other conditions that, in the investigator's judgment, would seriously endanger the patient's safety or affect the patient's completion of the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    digoxin, Rosuvastatin calcium,SHR3680

    Drug: SHR3680 · Drug: digoxin · Drug: Rosuvastatin calcium

  • Experimental
    metformin hydrochloride ,SHR3680

    Drug: SHR3680 · Drug: metformin hydrochloride

Interventions

06

What researchers measure

Primary outcomes

  1. Summary of Pharmacokinetic parameters Maximum Plasma concentration (Cmax) for digoxin, Rosuvastatin calcium, metformin hydrochloride

    Time frame: For digoxin and Rosuvastatin calcium group:Day1 and Day22;For metformin hydrochloride group:Day1 and Day19

  2. Summary of Pharmacokinetic parameters Area Under the Plasma Concentration-time Curve form 0 to any time before the last quantifiable concentration(AUC0-t)for digoxin, Rosuvastatin calcium, metformin hydrochloride

    Time frame: For digoxin and Rosuvastatin calcium group:Day1 and Day22;For metformin hydrochloride group:Day1 and Day19

  3. Summary of Pharmacokinetic parameters Area Under the Plasma Concentration-time Curve form 0 to infinite time(AUCinf)for digoxin, Rosuvastatin calcium, metformin hydrochloride

    Time frame: For digoxin and Rosuvastatin calcium group:Day1 and Day22;For metformin hydrochloride group:Day1 and Day19

Secondary outcomes

  1. Tmax of digoxin, Rosuvastatin calcium, metformin hydrochloride

    Time frame: For digoxin and Rosuvastatin calcium group:Day1 and Day22;For metformin hydrochloride group:Day1 and Day19

  2. incidence of adverse events/serious adverse event

    safety evaluation based on NCI-CTC AE 5.0

    Time frame: From ICF signing date to approximate 2 months

  3. T1/2 of digoxin, Rosuvastatin calcium, metformin hydrochloride

    Time frame: For digoxin and Rosuvastatin calcium group:Day1 and Day22;For metformin hydrochloride group:Day1 and Day19

  4. CL/F of digoxin, Rosuvastatin calcium, metformin hydrochloride

    Time frame: For digoxin and Rosuvastatin calcium group:Day1 and Day22;For metformin hydrochloride group:Day1 and Day19

  5. Vz/F of digoxin, Rosuvastatin calcium, metformin hydrochloride

    Time frame: For digoxin and Rosuvastatin calcium group:Day1 and Day22;For metformin hydrochloride group:Day1 and Day19

07

Study locations

1 site
  • Affiliated Hospital of Qingdao University
    Qingdao, Shandong 266003, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Sep 2021, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2020
First posted
Nov 9, 2020
StartActual
Jan 8, 2021
Primary completionActual
Sep 8, 2021
CompletionActual
Sep 8, 2021
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04621669
Responsible party
Sponsor
First posted
Nov 9, 2020
Start date
Jan 8, 2021
Primary completion
Sep 8, 2021
Completion
Sep 8, 2021
Last update
Jun 5, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rezvilutamide

Start the discussion